CN102574843B - 抗纤维化剂的稠环类似物 - Google Patents

抗纤维化剂的稠环类似物 Download PDF

Info

Publication number
CN102574843B
CN102574843B CN201080047294.3A CN201080047294A CN102574843B CN 102574843 B CN102574843 B CN 102574843B CN 201080047294 A CN201080047294 A CN 201080047294A CN 102574843 B CN102574843 B CN 102574843B
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
mmol
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080047294.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102574843A (zh
Inventor
斯彭切尔·约翰·威廉斯
史蒂文·扎米特
达伦·詹姆斯·凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celta Medical Co ltd
Original Assignee
Fibrotech Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrotech Therapeutics Pty Ltd filed Critical Fibrotech Therapeutics Pty Ltd
Priority to CN201510259423.XA priority Critical patent/CN105153188B/zh
Publication of CN102574843A publication Critical patent/CN102574843A/zh
Application granted granted Critical
Publication of CN102574843B publication Critical patent/CN102574843B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201080047294.3A 2009-10-22 2010-10-21 抗纤维化剂的稠环类似物 Expired - Fee Related CN102574843B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510259423.XA CN105153188B (zh) 2009-10-22 2010-10-21 抗纤维化剂的稠环类似物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25388909P 2009-10-22 2009-10-22
US61/253,889 2009-10-22
PCT/AU2010/001398 WO2011047432A1 (en) 2009-10-22 2010-10-21 Fused ring analogues of anti-fibrotic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510259423.XA Division CN105153188B (zh) 2009-10-22 2010-10-21 抗纤维化剂的稠环类似物

Publications (2)

Publication Number Publication Date
CN102574843A CN102574843A (zh) 2012-07-11
CN102574843B true CN102574843B (zh) 2015-06-17

Family

ID=43899730

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080047294.3A Expired - Fee Related CN102574843B (zh) 2009-10-22 2010-10-21 抗纤维化剂的稠环类似物
CN201510259423.XA Expired - Fee Related CN105153188B (zh) 2009-10-22 2010-10-21 抗纤维化剂的稠环类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510259423.XA Expired - Fee Related CN105153188B (zh) 2009-10-22 2010-10-21 抗纤维化剂的稠环类似物

Country Status (7)

Country Link
US (2) US9062076B2 (https=)
EP (2) EP2491030B1 (https=)
JP (3) JP5904944B2 (https=)
CN (2) CN102574843B (https=)
IN (1) IN2012DN03312A (https=)
SG (1) SG10201501272SA (https=)
WO (1) WO2011047432A1 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MX352516B (es) 2006-07-05 2017-04-06 Fibrotech Therapeutics Pty Ltd Compuestos terapeuticos.
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
CA2758071C (en) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CN102574843B (zh) 2009-10-22 2015-06-17 法博太科制药有限公司 抗纤维化剂的稠环类似物
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
NZ609144A (en) 2010-11-24 2014-08-29 Occurx Pty Ltd Methods of treating eye diseases associated with inflammation and vascular proliferation
WO2012083246A1 (en) 2010-12-17 2012-06-21 Agios Pharmaceuticals, Inc. Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
ES2569712T3 (es) 2010-12-21 2016-05-12 Agios Pharmaceuticals, Inc. Activadores de PKM2 bicíclicos
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CN103608016A (zh) 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
SMT202400081T1 (it) 2011-05-03 2024-03-13 Agios Pharmaceuticals Inc Attivatori della piruvato chinasi per uso in terapia
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
NZ702618A (en) * 2012-06-27 2016-12-23 4Sc Discovery Gmbh Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
FR2994184B1 (fr) * 2012-08-02 2017-12-08 Biomerieux Sa Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride aza-isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AR097279A1 (es) * 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
EP3046909A4 (en) 2013-09-17 2017-03-29 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6408569B2 (ja) 2013-10-17 2018-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104761506B (zh) * 2015-04-10 2017-05-03 温州大学 一种2‑(1‑苯乙烯基)喹唑啉酮化合物及其合成方法
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
KR102699521B1 (ko) 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
CN105175416B (zh) * 2015-10-20 2017-12-22 中国药科大学 一种新型的组蛋白去乙酰化酶抑制剂
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
JP7185631B2 (ja) 2017-02-03 2022-12-07 サータ セラピューティクス プロプライエタリー リミテッド 抗線維化化合物
GB201721961D0 (en) * 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
NZ766594A (en) 2018-01-31 2025-12-19 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN110483432A (zh) * 2018-05-14 2019-11-22 中国科学院上海药物研究所 一类丙烯酸类化合物及其制备方法、药物组合物和用途
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EP3810139A1 (en) 2018-06-21 2021-04-28 HepaRegeniX GmbH Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
IL279641B2 (en) 2018-07-16 2024-04-01 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2
CN109705140A (zh) * 2019-01-08 2019-05-03 荆楚理工学院 一种吡啶并[2,3-d][1,3]噁嗪衍生物的合成方法
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CN114831977B (zh) * 2021-02-02 2023-12-19 北京大学 苯甲酸类衍生物作为trpm2蛋白抑制剂的用途
CN114853684A (zh) * 2021-02-03 2022-08-05 北京万全德众医药生物技术有限公司 一种卢美派隆中间体的纯化方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN118239959A (zh) * 2022-12-23 2024-06-25 上海深势唯思科技有限责任公司 环丙烷类tlr7和8抑制剂及其制备方法和用途
CN118878452B (zh) * 2024-07-08 2025-01-24 徐州市第一人民医院 一种异吲哚啉酮衍生不饱和亚胺类化合物及其合成方法与在抗肿瘤活性中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769384A (en) * 1985-07-03 1988-09-06 Nippon Shinyaku Co. Ltd. Benzimidazole derivatives
EP1460067A1 (en) * 2001-11-26 2004-09-22 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
WO2004096757A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2006094235A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
EP1864972A1 (en) * 2005-03-30 2007-12-12 Kabushiki Kaisha Yakult Honsha Bcrp/abcg2 inhibitor
WO2008003141A1 (en) * 2006-07-05 2008-01-10 Fibrotech Therapeutics Pty Ltd Therapeutic compounds
WO2009079011A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640710B2 (https=) 1973-01-18 1981-09-22
JPS5830302B2 (ja) 1974-04-16 1983-06-28 キツセイヤクヒンコウギヨウ カブシキガイシヤ シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ
JPS5848545B2 (ja) 1974-04-18 1983-10-28 キツセイヤクヒンコウギヨウ カブシキガイシヤ シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ
JPS511440A (ja) 1974-04-18 1976-01-08 Kissei Pharmaceutical Shinkihokozokukarubonsanjudotai no seizohoho
GB1484413A (en) 1974-04-18 1977-09-01 Kissei Pharmaceutical Aromatic amidocarboxylic acid derivatives
JPS5855138B2 (ja) 1975-12-31 1983-12-08 キツセイヤクヒンコウギヨウ カブシキガイシヤ ホウコウゾクカルボンサンアミドユウドウタイノセイゾウホウホウ
JPS6019738B2 (ja) 1978-03-20 1985-05-17 久光製薬株式会社 新規なアントラニル酸誘導体
JPS5576852A (en) 1978-12-01 1980-06-10 Hisamitsu Pharmaceut Co Inc Novel derivative of anthranilic acid
JPS5817186B2 (ja) 1981-01-23 1983-04-05 キツセイ薬品工業株式会社 新規芳香族カルボン酸誘導体の製造方法
US4587356A (en) 1981-09-01 1986-05-06 Kissei Pharmaceutical Co., Ltd. Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives
JPS6019754A (ja) 1983-07-14 1985-01-31 Kissei Pharmaceut Co Ltd 芳香族カルボン酸アミド誘導体の製造方法
JPS60152454A (ja) 1984-01-18 1985-08-10 Terumo Corp アミド誘導体およびこれを有効成分として含有する５−リポキシゲナ−ゼ作用阻害剤
JPS6191163A (ja) * 1984-10-08 1986-05-09 Fujimoto Seiyaku Kk アントラニル酸誘導体の製造方法
DE3505609A1 (de) * 1985-02-19 1986-08-21 Merck Patent Gmbh, 6100 Darmstadt Benzimidazolyl-pyridazinone
JPH0692353B2 (ja) 1987-05-26 1994-11-16 マルコ製薬株式会社 新規なアミノ安息香酸アミド誘導体およびその製造法
JPS6416755A (en) 1987-06-23 1989-01-20 Biogal Gyogyszergyar Manufacture of n-(3',4'-dimethoxycinnamoyl)-aniline derivative
JPH01287066A (ja) 1988-05-13 1989-11-17 Fujimoto Seiyaku Kk 新規なアントラニル酸誘導体
JPH07116029B2 (ja) 1989-04-04 1995-12-13 キッセイ薬品工業株式会社 トラニラスト水溶液製剤
ES2100943T3 (es) 1990-02-08 1997-07-01 Eisai Co Ltd Derivado de bencenosulfonamida.
US5248825A (en) 1990-09-20 1993-09-28 Merrell Dow Pharmaceuticals Inc. Calcium uptake inhibitors
DE4115184A1 (de) 1991-05-09 1992-11-12 Bayer Ag Benzothiophen-2-carboxamid-s,s-dioxide
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
DK0657422T3 (da) 1993-12-09 1998-10-12 Ono Pharmaceutical Co Naphthyloxyeddikesyrederivater som PEG2-agonister og -antagonister
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
AU699489B2 (en) 1994-10-12 1998-12-03 Euro-Celtique S.A. Novel benzoxazoles
JPH08113567A (ja) 1994-10-17 1996-05-07 Sando Yakuhin Kk フェニルエテニル誘導体及びこれを含有する５−リポキシゲナーゼ阻害剤
US6444694B1 (en) * 1995-06-06 2002-09-03 Wyeth Styryl benzimidazole derivatives
JPH08337523A (ja) 1995-06-14 1996-12-24 Taiho Yakuhin Kogyo Kk 血管新生阻害剤
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
ATE222759T1 (de) 1996-02-07 2002-09-15 Lead Chem Co Ltd Tranilast enthaltendes externum und verfahren zu dessen herstellung
KR19990082523A (ko) 1996-02-15 1999-11-25 간자와 무츠와 혈관생성 억제제
JPH09278653A (ja) 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
DE19624155A1 (de) 1996-06-18 1998-01-08 Hoechst Ag Substituierte Benzoesäurederivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten
GB9625913D0 (en) * 1996-12-13 1997-01-29 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their seco precursors,and their use as prodrugs
JPH10259129A (ja) 1997-01-16 1998-09-29 Kissei Pharmaceut Co Ltd 血管新生阻害剤
FR2759368B1 (fr) 1997-02-10 2001-06-01 Galderma Rech Dermatologique Composes biaromatiques, compositions les contenant et utilisations
JPH10306024A (ja) 1997-03-07 1998-11-17 Kissei Pharmaceut Co Ltd 糸球体疾患の予防および治療剤
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
JPH10330254A (ja) 1997-04-01 1998-12-15 Kissei Pharmaceut Co Ltd 翼状片の進行および術後の再発抑制剤
US6127392A (en) 1997-08-05 2000-10-03 American Home Products Corporation Anthranilic acid analogs
JPH11180952A (ja) * 1997-12-19 1999-07-06 Maruho Co Ltd ２−オキシインドール誘導体
JP3256513B2 (ja) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US6444617B1 (en) * 1998-07-28 2002-09-03 Nihon Nohyaku Co., Ltd. Fused-heterocycle dicarboxylic acid diamide derivatives or salts thereof, herbicide and usage thereof
AU1690100A (en) 1998-12-21 2000-07-12 Takeda Chemical Industries Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
DK1196397T3 (da) * 1999-06-02 2006-01-02 Nps Pharma Inc Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
DE19935219A1 (de) 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
WO2001012189A1 (en) 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
AU2001251083A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
GB0019950D0 (en) * 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
WO2002030894A2 (en) * 2000-09-19 2002-04-18 Taiho Pharmaceutical Co., Ltd. Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins
WO2002055454A2 (en) 2001-01-10 2002-07-18 Smithkline Beecham Corporation Process and product
GB2372986A (en) * 2001-01-17 2002-09-11 Xenova Ltd 2-oxo, 4-hydroxy pyrroles and quinolines
ES2247298T3 (es) 2001-01-23 2006-03-01 Eli Lilly And Company Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
US6646009B2 (en) 2001-02-28 2003-11-11 Temple University — Of Commonwealth System of Higher Education N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
AR034897A1 (es) * 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
JP4851671B2 (ja) 2001-10-11 2012-01-11 ニチバン株式会社 トラニラスト経皮吸収貼付剤およびその製造方法
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
US6759428B2 (en) * 2001-12-04 2004-07-06 Roche Palo Alto Llc Indole nitriles
JP2005518371A (ja) 2001-12-10 2005-06-23 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療に於けるこれらの使用
ATE425978T1 (de) * 2001-12-19 2009-04-15 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren
IL162533A0 (en) 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
EP1466891A1 (en) 2001-12-27 2004-10-13 Taisho Pharmaceutical Co., Ltd Carboxylic acid derivative
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
JP2004143134A (ja) 2002-02-13 2004-05-20 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
JP2004075614A (ja) * 2002-08-20 2004-03-11 Sankyo Co Ltd クロメン誘導体を含有する医薬
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003258491A1 (en) 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
DE10254872A1 (de) 2002-11-25 2004-06-03 Symrise Gmbh & Co. Kg Anthranilsäureamide und deren Derivate als kosmetische und pharmazeutische Wirkstoffe
CN1506359A (zh) 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
JP2006522744A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
JP5001650B2 (ja) 2003-07-11 2012-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンズイミダゾールカルボキサミド
US20050026944A1 (en) 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7250444B2 (en) 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
CN101445469B (zh) * 2003-09-24 2013-02-13 梅特希尔基因公司 组蛋白脱乙酰基酶抑制剂
WO2005030705A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
DE10346913A1 (de) 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
MXPA06014230A (es) 2004-06-08 2007-02-14 Univ Temple Heteroarilsulfonas y sulfonamidas y usos terapeuticos de las mismas.
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
WO2006012135A1 (en) 2004-06-24 2006-02-02 Janssen Pharmaceutica, N. V. Quaternary salt ccr2 antagonists
DE102004030987A1 (de) 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide
US7671077B2 (en) 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
ZA200700811B (en) 2004-08-06 2008-10-29 Otsuka Pharma Co Ltd Aromatic compound
JP2008518957A (ja) 2004-11-04 2008-06-05 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体作動薬、そのような化合物を含んでいる組成物及び治療方法
US20100041756A1 (en) 2004-11-17 2010-02-18 Michael Lionel Selley method of modulating b cell functioning
WO2006057922A2 (en) 2004-11-23 2006-06-01 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
ITMI20050261A1 (it) 2005-02-21 2006-08-22 Carlo Ghisalberti Analoghi strutturali di avenatramidi loro uso in composizioni utili nel trattamento di disordini dermatologici
WO2006102645A1 (en) 2005-03-24 2006-09-28 Janssen Pharmaceutica, N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
ITMI20050674A1 (it) 2005-04-15 2006-10-16 Univ Degli Studi Milano Uso di derivati ammidici come agenti modificatori del gusto composizioni aromatizzanti e prodotti che li contengono
MX2007014180A (es) * 2005-05-10 2008-01-14 Vertex Pharma Derivados biciclicos como moduladores de canales de iones.
BRPI0610349A2 (pt) 2005-05-16 2010-06-15 Angiogen Pharmaceuticals Pty L processos e composições para o tratamento de dor
WO2006134013A1 (en) 2005-06-14 2006-12-21 Symrise Gmbh & Co. Kg Mixtures comprising anthranilic acid amides and cooling agents as cosmetic and pharmaceutical compositions for alleviating itching
WO2007015744A1 (en) 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
EP1959915B1 (en) 2005-11-30 2015-05-13 Symrise AG Mixtures comprising anthranilic acid amides and antidandruff agents as cosmetic and pharmaceutical compositions for alleviating itching
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN101466670B (zh) * 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US20070286892A1 (en) 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
ES2462925T3 (es) 2006-06-14 2014-05-26 Symrise Ag Compuestos con efecto antimicrobiano para el tratamiento de fetidez oral
AU2007271486A1 (en) 2006-07-05 2008-01-10 Merck Patent Gmbh Sulfamate benzothiophene derivatives
KR100832747B1 (ko) 2006-10-27 2008-05-27 한국화학연구원 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
BRPI0718677A2 (pt) * 2006-11-03 2013-11-26 Irm Llc Compostos e composições como inibidores de quinases proteicas
WO2008073461A2 (en) 2006-12-11 2008-06-19 Wyeth Ion channel modulators
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008109238A1 (en) 2007-03-02 2008-09-12 Janssen Pharmaceutica N.V. Substituted cyclopentyl piperidine ccr2 antagonists
EP1972624A1 (en) 2007-03-23 2008-09-24 Clariant International Ltd. Benzoxazinones and their use as ultraviolet light absorbers
US20090239982A1 (en) 2007-03-30 2009-09-24 Fujifilm Corporation Ultraviolet Absorbent and Heterocyclic Compound
WO2008124153A1 (en) 2007-04-10 2008-10-16 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
CA2690410C (en) * 2007-06-12 2015-09-29 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
EP2030617A1 (en) 2007-08-17 2009-03-04 Sygnis Bioscience GmbH & Co. KG Use of tranilast and derivatives thereof for the therapy of neurological conditions
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
US20090170842A1 (en) * 2007-11-14 2009-07-02 University Of Kansas Brca1-based breast or ovarian cancer prevention agents and methods of use
WO2009068557A1 (en) 2007-11-28 2009-06-04 Neurosearch A/S Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators
US20090163586A1 (en) 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
CA2709937C (en) 2007-12-21 2016-03-22 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
CN101481323B (zh) 2008-01-11 2013-11-20 中国人民解放军军事医学科学院毒物药物研究所 苯并环庚烯类衍生物、其制备方法及医药用途
TWI392673B (zh) 2008-08-27 2013-04-11 Calcimedica Inc 調控細胞內鈣離子濃度之化合物
EP2179984A1 (en) 2008-10-27 2010-04-28 Congenia S.r.l. Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
CN101423503A (zh) 2008-12-04 2009-05-06 上海大学 2-(反式-2,3-二氢-2-芳基-1-氰基-3-甲氧羰基环丙烷)-1,3-苯并噻唑及其合成方法
WO2010103130A2 (en) 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
CN102574843B (zh) 2009-10-22 2015-06-17 法博太科制药有限公司 抗纤维化剂的稠环类似物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769384A (en) * 1985-07-03 1988-09-06 Nippon Shinyaku Co. Ltd. Benzimidazole derivatives
EP1460067A1 (en) * 2001-11-26 2004-09-22 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
WO2004096757A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2006094235A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
EP1864972A1 (en) * 2005-03-30 2007-12-12 Kabushiki Kaisha Yakult Honsha Bcrp/abcg2 inhibitor
WO2008003141A1 (en) * 2006-07-05 2008-01-10 Fibrotech Therapeutics Pty Ltd Therapeutic compounds
WO2009079011A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors

Also Published As

Publication number Publication date
CN102574843A (zh) 2012-07-11
SG10201501272SA (en) 2015-04-29
JP2018012700A (ja) 2018-01-25
EP2947073A3 (en) 2016-02-17
JP2013508306A (ja) 2013-03-07
CN105153188B (zh) 2018-06-01
EP2491030A1 (en) 2012-08-29
JP5904944B2 (ja) 2016-04-20
WO2011047432A1 (en) 2011-04-28
JP6215890B2 (ja) 2017-10-18
US9951087B2 (en) 2018-04-24
HK1217951A1 (zh) 2017-01-27
EP2491030A4 (en) 2013-04-17
JP6437060B2 (ja) 2018-12-12
JP2016128401A (ja) 2016-07-14
CN105153188A (zh) 2015-12-16
US20120270863A1 (en) 2012-10-25
US20130338151A9 (en) 2013-12-19
EP2947073A2 (en) 2015-11-25
HK1217480A1 (en) 2017-01-13
US20150266893A1 (en) 2015-09-24
IN2012DN03312A (https=) 2015-10-23
US9062076B2 (en) 2015-06-23
EP2947073B1 (en) 2019-04-03
EP2491030B1 (en) 2015-07-15

Similar Documents

Publication Publication Date Title
CN102574843B (zh) 抗纤维化剂的稠环类似物
JP2003508380A (ja) スルホニルカルボキサミド誘導体、その調製方法および医薬としてのその使用
CN109311865B (zh) 抗乙肝病毒的吡唑-噁唑烷酮类化合物
CA2651128A1 (en) Benzimidazole modulators of vr1
KR20010042434A (ko) 술폰아미드 함유 인돌 화합물
CN110267940A (zh) 四取代的烯烃化合物和它们的用途
AU2020424661B2 (en) Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient
CN114401935B (zh) 离子通道拮抗剂/阻断剂及其用途
CN111777501A (zh) 咖啡酸苯乙酯类衍生物，其制法和其药物组合物与用途
JP7334979B2 (ja) イソプレニルシステインカルボキシルメチルトランスフェラーゼ阻害剤として有用な化合物
HK1217951B (en) Fused ring analogues of anti-fibrotic agents
TWI624466B (zh) 苯并噻吩化合物
CN116813603B (zh) 一种选择性雌激素受体α降解化合物及其制备方法和应用
HK1217480B (en) Fused ring analogues of anti-fibrotic agents
WO2016019588A1 (en) Oxacazone compounds to treat clostridium difficile
HK40092869A (zh) 氘代化合物
HK40092869B (zh) 氘代化合物
HK1215570B (en) Bensothiophene compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20191024

Address after: Victoria, Australia

Patentee after: CELTA Medical Co.,Ltd.

Address before: Victoria, Australia

Patentee before: Fibrotech Therapeutics Pty Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150617

CF01 Termination of patent right due to non-payment of annual fee